Intrabone Cord Blood Transplantation

Hospital Clinic of Barcelona10 enrolled

Overview

The purpose of this study is to evaluate the viability of intrabone administration of umbilical cord blood as allogenic transplantation for the treatment of hematologic malignancies.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hematological Malignancies

Interventions

Intrabone administration of umbilical cord bloodPROCEDURE

Single administration

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hematological malignancies * Indication of allogenic transplantation * No suitable donor (related/unrelated) * No suitable cord blood unit with enough cellularity for standard transplant * Written informed consent Exclusion Criteria: * ECOG \> 2 * Co-morbidities * HIV positive serology * Pregnancy or breastfeeding * Psychiatric illness

Locations (1)

BMT Unit Hematology Department Hospital Clinic

Barcelona, Barcelona, Spain

RECRUITING

Outcomes

Primary Outcomes

Kinetics of hematopoietic engraftment

Time frame: days 14, 21, 28 after administration

Secondary Outcomes

Dynamics and chimerism of hematological engraftment

Time frame: days 14, 21, 28 after administration

Central Contacts

Montserrat Rovira, MD

CONTACT

+34932275428 mrovira@clinic.ub.es

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.